Trial Profile
CLARITY: Assessment of VenetoCLAx (ABT-199) in combination with IbRutInib in relapsed/refracTory Chronic LymphocYtic Leukaemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 May 2023
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms CLARITY
- 13 Dec 2022 Results of exploratory analysis of this study presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 04 Apr 2022 Status changed from active, no longer recruiting to completed.
- 14 Dec 2021 Planned End Date changed from 1 Dec 2021 to 1 Apr 2022.